课题基金 / 基金详情

DNA Topoisomerases as Target of Action of Anticancer Dru

DNA Topoisomerases as Target of Action of Anticancer Dru
DNA拓扑异构酶作为抗癌药物的作用靶点
批准号:
6558979
负责人:
YVES POMMIER
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

YVES POMMIER的其他基金

相似基金

相关文献

中文摘要
翻译
DNA拓扑异构酶(top1和top2)是一些最有效的抗癌药物的靶点。TOP2抑制剂、依托泊苷和DNA嵌入剂(如阿霉素及其衍生物)是当今最常用的抗癌药物。喜树碱是一种特殊的TOP1毒药,最近已被FDA批准用于治疗对先前化疗耐药的人类癌症。本项目的目标是:i)阐明拓扑异构酶抑制剂与其靶标酶之间的分子相互作用;ii)阐明响应拓扑异构酶介导的DNA损伤的分子途径并有助于提高拓扑异构酶抑制剂在癌细胞中的选择性;iii)发现新的拓扑异构酶抑制剂。 目的1:为了阐明拓扑异构酶抑制剂与其靶酶之间的分子相互作用,我们建立了重组top1的杆状病毒表达系统。我们将这种top1酶与含有一个模拟拓扑异构酶抑制剂的多环芳香加合物的寡核苷酸一起使用,发现top1裂解位置的插层与喜树碱的作用相似。基于分子模拟和晶体结构数据,我们提出了多环芳香族化合物嵌入DNA中,并稳定了DNA碱基脱离DNA双链的中间体。阐明药物结合位点的第二种方法是鉴定选择性地赋予喜树碱耐药性的top1突变。对喜树碱耐药的人前列腺癌细胞株(DU145/RC.1&1)的分析表明,top1的364个氨基酸残基对喜树碱的活性(与top1?相互作用)是重要的。在这些细胞中,精氨酸364突变为组氨酸,通过突变的重组top1酶和在细胞中都赋予了对喜树碱的高耐药性。 目标2:为了阐明响应拓扑异构酶介导的DNA损伤的分子途径,我们启动了一种新发现的酶-酪氨酰-DNA-磷酸二酯酶(TDP-1)的研究,该酶能选择性地去除DNA 3‘端结合的酪氨酸残基。我们与巴塞罗那大学的格兰达斯博士和美国国立卫生研究院的纳什博士合作发现,当Top1肽较短且与较长的DNA寡核苷酸相连时,TDP-1的活性最佳。这表明TDP-1的催化部位既与DNA相互作用,又与短肽片段相互作用。这些发现强调了在细胞中TDP-1作用之前Top1蛋白降解的潜在重要性。我们还使用了新的微阵列技术来阐明决定细胞反应的细胞途径,更重要的是,细胞杀伤或对拓扑异构酶抑制剂的耐药性。我们发现,对喜树碱的转录反应会影响导致细胞周期停滞或凋亡的RNA,这取决于药物的剂量和生存结果。我们还发现,在对喜树碱耐药的前列腺癌细胞中,程序性细胞死亡(细胞凋亡)明显减少。 目标3:我们一直致力于新型拓扑异构酶I抑制剂的发现和分子药理学研究。首先,在喜树碱方面,我们已经确定了新的喜树碱,它们在血液中具有更高的稳定性,应该是有用的临床候选药物。我们还与杜克大学的Gamcsik博士和三角研究所的WALL博士合作,发现了新的喜树碱-多肽结合物(结合在喜树碱第7位的谷胱甘肽),可以产生非常稳定的top1裂解复合体。这些化合物已经申请了专利,因为它们可以用来专门向肿瘤细胞输送药物。其次,我们继续对我们与库什曼博士合作发现的吲哚异喹啉进行研究。我们最近获得了一种与拓扑异构酶I-DNA复合体结合的吲哚咔唑的共晶。我们现在有更多有效的TOP1毒药,正在进行临床前开发的研究。
英文摘要
DNA topoisomerases (top1 & top2) are the targets for some of the most effective anticancer therapeutics. The top2 inhibitors, etoposide and DNA intercalators (such as adriamycin and derivatives) are the most commonly used anticancer drugs today. Camptothecins are specific top1 poisons and have recently been approved by the FDA for the treatment of human carcinomas resistant to prior chemotherapy. The goals of this project are: i) to elucidate the molecular interactions between topoisomerase inhibitors and their target enzymes, ii) to elucidate the molecular pathways that respond to topoisomerase-mediated DNA damage and contribute to the selectivity of topoisomerase inhibitors in cancer cells, and iii) discover novel topoisomerase inhibitors. Goal 1: To elucidate the molecular interactions between topoisomerase inhibitors and their target enzymes, we have set up a baculovirus expression system for high expression of recombinant top1. We have used this top1 enzyme with oligonucleotides containing a single polycyclic aromatic adduct that mimics a topoisomerase inhibitor, and found that intercalation at the site of top1 cleavage mimics the effect of camptothecin. Based on molecular modeling and crystal structure data, we proposed that polycyclic aromatics intercalate in the DNA and stabilize an intermediate in which a DNA base is flipped out of the DNA duplex. A second approach to elucidate the drug binding sites has been to identify top1 mutations that selectively confer camptothecin resistance. Analysis of camptothecin-resistant human prostate carcinoma cell lines (DU145/RC.1 & 1) demonstrated that amino acid residue 364 of top1 is important for camptothecin activity (interaction with top1?). In these cells, mutation of arginine 364 to histidine confers high resistance to camptothecin both with the mutated recombinant top1 enzyme and in cells. Goal 2: To elucidate the molecular pathways that respond to topoisomerase-mediated DNA damage, we have initiated studies with a newly discovered enzyme, tyrosyl-DNA-phosphodiesterase (TDP-1) that selectively removes the tyrosyl residue bound at the 3'-end of the DNA. In collaboration with Dr. Grandas (University of Barcelona) and Dr. Nash (NIH), we found that the activity of TDP-1 is optimum when the top1 peptide is short and when it is linked to a long DNA oligonucleotide. This suggests that the catalytic site of TDP-1 interacts both with the DNA and a short peptide segment. These findings underline the potential importance of top1 proteolysis prior to TDP-1 action in cells. We have also used the new microarray technology to elucidate the cellular pathways that determine cellular response and more importantly, cellular killing or resistance to topoisomerase inhibitors. We found that the transcriptional response to camptothecin affects RNAs that drive cell cycle arrest or apoptosis, depending on the dose of drug and survival outcome. We have also found that programmed cell death (apoptosis) is markedly attenuated in prostate cancer cells that are resistant to camptothecins. Goal 3: We have pursued our investigations for the discovery and molecular pharmacology investigations of novel topoisomerase I inhibitors. First, in the areas of camptothecins, we have identified novel camptothecins with enhanced stability in the bloodstream and which should be useful clinical candidates. We have also discovered in collaboration with Dr. Gamcsik (Duke University) and Dr. Wall (Research Triangle Institute) new camptothecin-peptide conjugates (glutathione bound to position 7 of camptothecin) that produce remarkably stable top1 cleavage complexes. These compounds have been patented because they can be used to specifically deliver drugs to the tumor cells. Secondly, we have continued our studies on the indenoisoquinolines that we discovered in collaboration with Drs Cushman. We recently obtained co-crystals of one of the indolocarbazoles bound to the topoisomerase I-DNA complex. We now have more potent top1 poisons that are being investigated for pre-clinical development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHARMACOLOGY OF HIV VIRAL DNA & RETROVIRAL INTEGRASES
Pharmacology of HIV Viral DNA & Retroviral Integrases
Pharmacology of HIV Viral DNA & Retroviral Integrases
Pharmacology of HIV Viral DNA & Retroviral Integrases
海外基金